Daraxonrasib Approved for Metastatic Pancreatic Cancer
Key Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Summary Spanish researchers report complete tumour elimination in mouse models of aggressive Pancreatic Cancer A triple-drug combination therapy prevented
Read MoreResearchers at Memorial Sloan Kettering Cancer Center (MSK) have uncovered a surprising link between pregnancy-specific glycoproteins (PSGs) and poorer lung
Read More